Circulation Impact Factor

Circulation's JIF has been remarkably stable in the upper cardiology tier since 2021. The jump from 29.7 in 2020 to 39.9 in 2021 reflects the wave of heavily cited COVID-cardiovascular papers that boosted many cardiology journals. It rose from 38.6 in the prior JCR data year to a 2025 JIF of 41.3, so the current number is not a retreat from the post-pandemic cardiology tier.

The five-year JIF (40.5) sitting slightly below the two-year (41.3) is normal for a journal whose papers generate strong initial citations. Clinical cardiology papers tend to be cited most heavily in the first two years, particularly large trials and guideline-adjacent studies. That early-citation pattern is a feature of the field, not a weakness of the journal.

An impact factor of 41.3 places Circulation in the top echelon of all medical journals, not just cardiology. For context, NEJM is at 84.5 and The Lancet is at 109, but those are general medicine journals that draw citations from every specialty. Within cardiovascular medicine specifically, 41.3 places Circulation among the top three journals in its category.

The number tells you that Circulation papers are cited intensively and quickly. What it doesn't tell you is whether your specific paper will match that average. Citation distribution within the journal is skewed: large trials and guideline papers generate hundreds or thousands of citations, while smaller studies may accumulate far fewer. The JIF is a journal-level average, not a prediction for any individual paper.

For manuscripts targeting Circulation, three patterns account for most of the desk rejections we see.

Clinically sound studies that stop short of a practice consequence.

Circulation's documented desk rejection rate is commonly estimated around 70-75%. The editorial team makes most of those decisions quickly, median immediate rejection time is 9 days according to SciRev author reports. What triggers fast rejection is not poor science but the absence of a clear practice consequence for a broad cardiovascular audience. The explicit editorial standard, confirmed across AHA editorial communications and documented in submission guidance, is whether the work changes how a broad cardiovascular audience interprets practice, prognosis, or disease biology.

We see well-designed observational cohort studies, imaging studies, and mechanistic translational papers that are technically rigorous but whose conclusion is primarily relevant to one subspecialty audience. Papers reporting on a novel biomarker in a specific cardiac phenotype, or validating an imaging protocol in a single-center population, frequently hit this wall regardless of methodological quality.

The distinction Circulation editors draw is between papers that add evidence for what is already being discussed and papers that move the cardiovascular conversation forward in a way the whole field will feel.

Statistical design and reporting issues that survive initial review but fail independent statistical evaluation.

Circulation's editorial office is documented to send papers for independent statistical review when warranted. The specific red flags they evaluate include: post-hoc analyses submitted as if they were pre-specified primary endpoints, uncorrected multiple testing across a large number of secondary endpoints, and missing confidence intervals on the primary findings. We see papers where the main claim relies on a subgroup analysis that was identified after the data were available, with the statistical presentation written as if the hypothesis drove the design.

Circulation reviewers are calibrated to the methodological standards of major clinical trial reporting (CONSORT, STROBE), and papers that cannot distinguish clearly between primary and exploratory analyses put themselves in a difficult position regardless of the headline result. The practical fix is making the pre-specification explicit and presenting post-hoc findings as clearly labeled exploratory rather than weaving them into the primary narrative.

Subspecialty-dominant papers submitted to the flagship instead of the AHA family journal that actually fits.

The AHA Circulation family has titles for arrhythmia and electrophysiology (Circ: Arrhythmia and Electrophysiology, JIF 9.3), heart failure (Circ: Heart Failure, JIF 8.3), interventional cardiology (Circ: Cardiovascular Interventions, JIF 7.2), and imaging (Circ: Cardiovascular Imaging, JIF 9.1). Circulation's scope is explicitly broad cardiovascular, not broad by the standards of a subspecialty community but broad by the standards of the cardiologist who needs to read across all of these domains.

We see EP papers, heart failure device studies, and advanced imaging protocols submitted to Circulation because the authors read the impact factor as a quality signal rather than a scope signal. Circulation's documented editorial response to these papers is usually a suggestion to submit to the more appropriate subspecialty title within the AHA portfolio. Understanding this family structure before choosing where to submit is the simplest available intervention for avoiding a predictable desk rejection.

Circulation editors screen for papers that change cardiovascular practice, interpretation, or understanding at a level the broad cardiology community will care about. Technical quality alone doesn't clear the bar. The question is always: does this change what cardiologists do or think?

What gets past the desk:

• Large clinical trials with clear practice implications

• Studies that address questions cardiologists are actively debating

• Translational work with a convincing bridge to clinical relevance

• Epidemiological findings that reshape cardiovascular risk understanding

• Guideline-adjacent evidence from well-powered designs

What gets desk-rejected:

• Strong physiology or imaging papers where the consequence feels too narrow

• Small single-center studies without broader generalizability

• Basic science without clear translational framing

• Incremental findings that don't move a clinical conversation forward

Submit if:

• The paper matters to a broad cardiovascular audience, not just one subspecialty

• There's clear consequence for clinical interpretation, prognosis, or management

• The study design is strong enough to survive the most demanding peer review

• The manuscript can stand in the top cardiology conversation globally

Think twice if:

• The work is strong but mostly relevant within one subspecialty (consider a Circulation subspecialty journal instead)

• The clinical consequence is still indirect or speculative

• A top subspecialty journal (Circulation Research, JACC subspecialty journals) would actually serve the audience better

• European Heart Journal is the more natural home based on registry data, population, or guideline alignment

For high-stakes cardiology submissions, running a Circulation clinical significance check can clarify whether the framing and clinical consequence are strong enough for this bar.

Circulation sits at the top of an AHA journal family that includes several subspecialty titles:

This family structure is useful strategically. If a manuscript is strong but too narrow for the flagship, Circulation editors sometimes suggest transfer to a subspecialty title. Understanding this cascade can help authors plan realistic submission strategies rather than treating a Circulation desk rejection as the end of the road.

• Whether the paper is broad enough for Circulation's audience

• Whether the editorial triage will see it as too subspecialized

• How the paper compares against what Circulation has been publishing recently

• Whether European Heart Journal or JACC is actually the better fit

• How long the review process will take (varies widely)

The JIF is a citation average. It doesn't predict editorial decisions, and it doesn't tell you anything about the specific editorial culture or recent publication patterns at the journal.

This page is most useful when you read it alongside the next-step pages in the same journal cluster:

• Circulation submission process

• Circulation review time

• Circulation under review